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Abstract Severe sepsis and septic shock remains a
leading cause of mortality and morbidity in children. There
is ongoing uncertainty regarding the optimal treatment
pathways however the initial management of sepsis is
crucial. This article is designed to be an informal and
personal review of recent developments in paediatric sepsis
over the past 3 years.
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Introduction
Severe sepsis and septic shock remains a leading cause of
mortality and morbidity in children. Despite advances in
prevention and treatment, children with severe sepsis
continue to present significant treatment challenges to
clinicians. Current treatment guidelines have been devel-
oped from the best available evidence ranging from mul-
tiple large randomized controlled trials to consensus of
expert opinion, often extrapolating from adult data.
Research is ongoing in many aspects of sepsis in both
the adult and paediatric population.
This article is designed to be an informal and personal
review of recent developments in paediatric sepsis over the
past 3 years.
Current Experience
Over the last 10 years or so, the epidemiology of paediatric
severe sepsis has been dramatically affected by the intro-
duction of effective vaccines against what were the most
common causes of community-acquired sepsis in children.
Beginningwith the introduction of the HiB (Haemophilus
influenzae type B) vaccine into the routine schedule of infant
vaccines in the early 1990s, and subsequent introduction of
theMen C (serogroup Cmeningococcal) vaccine and then 7-
and 13-valent pneumococcal vaccines and the recent intro-
duction of theMen B (serogroup Bmeningococcal) vaccine,
the whole pattern of admissions to PICU with severe sepsis
has completely changed.
It is becoming increasingly common that patients
admitted to paediatric intensive care with severe sepsis in
this current post-vaccine era are those with extreme pre-
maturity, pre-existing co-morbidities or who are immuno-
compromised in some way [1•].
Because of this change in epidemiology, understanding
the pathophysiology of paediatric sepsis has proven more
difficult, and rational interventions to interrupt the ‘‘sepsis
cascade’’ have proven less effective than predicted, prob-
ably because these children are not previously healthy with
community-acquired sepsis, but are a heterogeneous mix-
ture of patients with varied pathologies.
It is likely that more generic measures or ‘‘bundles of
care’’, such as are recommended in tools such as the ‘‘Sur-
viving Sepsis Campaign’’, will prove beneficial in paediatric
practice, as they have been shown to be in adult practice [2••].
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Surviving Sepsis Campaign
Current guidelines regarding the treatment of sepsis have
been dominated by successive Surviving Sepsis Campaign
(SSC) publications, the latest in 2012 [2••]. These recom-
mendations have been developed with significant multi-na-
tional representation and cooperation. The recommendations
are the product of systematic reviews of the evidence and
expert opinion following extensive literature review.
The surviving sepsis campaign recommendations focus
on early identification of severe sepsis and septic shock,
prompt administration of IV antibiotics with haemody-
namic resuscitation and then ongoing supportive care.
Paediatric recommendations differ from the adult rec-
ommendations where there is specific evidence relating to
children available or where it is felt that evidence from
adult studies would be inappropriate to extrapolate. The
Paediatric Considerations in the campaign differ from the
adult guidance on several issues. These include recom-
mendations in children for the use of intraosseous access
and peripheral vasoactive infusions when there is difficulty
in gaining central venous access; the rapidity of fluid
resuscitation; the type and dose of vasoactive infusions and
the use of lung protective ventilation strategies.
The American College of Critical Care Medicine has also
published Clinical Guidelines for Hemodynamic Support of
Neonates and Children with Septic Shock (ACCM) [3••].
These have the advantage of being specific for the neonatal
and paediatric populations, and many of their recommenda-
tions have been adopted by the Surviving Sepsis Campaign.
Both the SSC and ACCM guidelines are currently being
updated.
New Findings
Early Goal Directed Therapy
The identification of physiological targets in the immediate
management of patients with sepsis and septic shock has
been labelled ‘‘Early Goal Directed Therapy’’. The first
reliable evidence that targeting blood pressure, perfusion
(urine output) and central venous oxygen saturation was
beneficial to outcome (as determined by mortality) was
published in a landmark paper by Rivers et al. [4]. This was
a single-centre randomized, proof-of-concept trial which
showed that hospital mortality and length of hospital stay
are improved in patients with septic shock who are resus-
citated according to protocol-driven goal directed therapy.
The goals differed from standard goals by targeting central
venous oxygen saturation in addition to other more readily
available parameters. While early goal directed therapy
was readily adopted into Surviving Sepsis Campaign
guidelines, there remained controversy regarding the
external validity of the original trial, the difficulty of
implementation and potential complications of certain
aspects of the protocol. These controversies are particularly
relevant to the paediatric population, especially in regard to
the need to obtain early central venous access in the
superior thoracic distribution (internal jugular or subcla-
vian veins) for the measurement of central venous oxygen
saturation.
Three major trials concerning goal directed therapy have
been published in the past year in the New England Journal
of Medicine. These trials were undertaken across multiple
centres in the United States (ARISE), England (ProMISE)
and Australasia (ProCESS) [5••, 6••, 7••]. In total, over
4000 adult patients were enrolled in these trials comparing
early goal directed therapy to usual care. The ProCESS
trial also included a third arm of Protocol-Based Standard
therapy. Each trial independently found that the patients
who received early goal directed therapy had no significant
benefit in mortality, organ dysfunction or intensive care
stay compared with usual care or protocol-based care
(Table 1). It is important to state that in the 13 years since
the Rivers study was published, there have been huge
advances in the delivery of protocolised care to patients
with sepsis and septic shock, due to the broad uptake of the
SSC guidelines [8•]. This suggests that routine care for
these patients has dramatically improved, with consequent
improvement in outcomes, and suggests that despite good
evidence for the use of a central venous oxygen saturation
target, the benefit of achieving such a target is not
accompanied by demonstrable improvements in outcome
when compared with current standard care.
Whilst there were no paediatric patients enrolled in
these trials, they provide compelling evidence that goal
directed therapy in sepsis does not provide additional
benefit over usual care. A surrogate for measurement of
central venous oxygen saturation is measurement of whole
blood lactate. While this gives a measure of global oxygen
utilization, several studies have demonstrated the utility of
measuring lactate clearance as a marker of adequacy of
resuscitation and association with outcome, in both adults
and children [9–11].
Timing of Antibiotics
A long-held tenet of the treatment of septic shock has been
the early administration of empiric antibiotics.
A large international multicentre trial looking at almost
18,000 adult patients with severe sepsis or septic shock
demonstrated a significant correlation between delay in
antibiotic administration and mortality, increased illness
severity and organ dysfunction [12••]. This study
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demonstrated that the odds ratio for death increased steadily
each hour antibiotics were delayed (see Table 2). This is a
timely confirmation that the timing of antibiotic therapy is
still paramount once septic shock and severe sepsis has been
recognized. A recent paediatric study has demonstrated a
similar correlation between delayed antibiotic administra-
tion and risk of organ dysfunction [13•].
Fluid Resuscitation
Following the publication of the Fluid Expansion as Sup-
portive Therapy (FEAST) Trial in 2011, which demon-
strated increased mortality in children with presumed
sepsis treated with fluid bolus therapy compared with
maintenance fluid, there has been intense interest in the
possible disadvantages of fluid overload in the treatment of
paediatric septic shock [14]. Given the population and
setting of the FEAST study, it is unclear how relevant this
study is to resource-rich settings.
Further rigorous and well-powered research is required
prior to any change in the current consensus. There is no
doubt that early, aggressive fluid resuscitation has been
associated with the improvements in outcome of severe
sepsis and septic shock that have been demonstrated [3••,
15]. Although rigorously conducted randomized controlled
trials are difficult to conduct in these circumstances, the
recent adult studies referred to above suggest that such
studies are possible, and this should be the priority in
paediatric practice. It is heartening that such a study, in
pilot form, has recently been funded by the UK National
Institute of Health Research [16].
Steroids
The use of steroids in sepsis has been an ongoing debate in
clinical practice and international literature. There are
pathophysiological reasons, including sepsis-associated
adrenal suppression, inotrope unresponsiveness and exag-
gerated inflammatory responses, which logically lead to the
conclusion that corticosteroid therapy should provide
multiple benefits to patients with shock. However, the
evidence base does not reflect this theory in practice.
There has been conflicting evidence regarding the ben-
efits of steroid use in adults with shock and no large ran-
domized controlled trials in a paediatric population. A
meta-analysis published in 2013 concluded that there is
very limited evidence to support the use of steroids in
paediatric septic shock [17•]. There is a considerable need
for well-designed and appropriately powered trials in
resource-rich settings to fully delineate the possible bene-
fits of steroid therapy, particularly in children.
Future Directions
Aside from trials looking into already established treatments,
there is also considerable interest in determining what patient
factors increase a child’s risk of a serious sepsis event.
Research into these patient characteristics remains explora-
tory but provides an exciting opportunity for the future
development of novel treatments or therapeutic approaches.
Genetics
There has been an explosion in the development of tech-
nology to allow research into the impact of genetics on the
susceptibility to, and severity of infections. Numerous
studies have evaluated gene polymorphisms in both the
adult and paediatric population with severe sepsis. Many of
these studies have demonstrated associations between dis-
ease severity and presence of various polymorphisms.
However, most of these studies have suffered from being
underpowered, having heterogenous populations and not
being able to validate the preliminary results [18].
The use of Genome-Wide studies has become possible
in the last 5 years, and further developments in technology
Table 1 Compiled mortality data of ProCESS, ProMISE and ACCESS trials
Any cause day 90 mortality—
no/total no (%)
EGDT Usual care Protocol-based
standard therapy
ProMISE 184/623 (29.5) 181/620 (29.2) –
ARISE 147/792 (18.6) 150/796 (18.8) –
ProCESS 129/405 (31.9) 139/412 (33.7) 128/415 (30.8)
Table 2 Hospital mortality odds ratios
Time to antibiotics Odds
ratio
95 % Confidence
interval
P value
0–1 1.00
1–2 1.07 0.97–1.18 0.165
2–3 1.14 1.02–1.26 0.021
3–4 1.19 1.04–1.35 0.009
4–5 1.24 1.06–1.45 0.006
5–6 1.47 1.22–1.76 \0.001
[6 1.52 1.36–1.70 \0.001
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will undoubtedly provide the possibility of offering per-
sonalized therapies [19]. Current technology allows the
dissection of genetic pathways within hours of sampling,
and this offers the possibility of intervening specifically to
influence particular pathways which have been activated or
suppressed in individual patients [20•].
Currently, this research does not yet have clinical
applications however in the future genetic testing may also
be useful in patient risk stratification.
Vitamin D
Vitamin D has been investigated in the context of several
conditions including asthma, eczema, respiratory tract
infections and sepsis.
There have been recent studies demonstrating associa-
tions between Vitamin D levels and severity of sepsis.
These studies have shown that children with low Vitamin
D levels were more likely to have sepsis, increased illness
severity and spend longer in PICU [21, 22•]. There is some
discussion around whether Vitamin D levels taken in
children with septic shock after significant fluid resuscita-
tion are reflective of their premorbid levels. A recent meta-
analysis in adults demonstrated similar findings [23].
The next stage of research impacting on treatment
guidelines would be an assessment of whether treatment of
Vitamin D deficiency whilst critically unwell reduces
PICU stay and improves prognosis.
Conclusion
Over the past 3 years, sepsis research has focused on initial
fluid resuscitation and goal directed therapy. There is an
ongoing need to extrapolate adult data to the paediatric
population. However, further research in a paediatric set-
ting is required to develop the optimal approach to resus-
citation. The main focus of ongoing research is focused on
genetic studies, which may lead to interesting new strate-
gies. The central tenets of paediatric sepsis management
remain constant with the confirmation of benefit of early
antibiotic administration and appropriate supportive ther-
apy as advised by international guidelines.
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